Vedolizumab and Anti-TNFs Outcomes in Real-World Biologic Ulcerative Colitis and Crohn's Disease Patients
Phase of Trial: Phase IV
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms EVOLVE-IBERIA
- Sponsors Takeda
- 17 Oct 2019 Planned End Date changed from 31 Oct 2019 to 30 Jun 2020.
- 17 Oct 2019 Planned primary completion date changed from 31 Oct 2019 to 30 Apr 2020.
- 08 Mar 2019 Status changed from not yet recruiting to recruiting.